Litcius/Paper detail

Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model

Zenan Zhang, Hongyue Zhou, Yu Liu, Jia Ren, Jingjing Wang, Qianyu Sang, Yue Lan, Yixuan Wu, Hongyan Yuan, Weihua Ni, Guixiang Tai

2021International Immunopharmacology13 citationsDOI

Topics & Concepts

ImmunotherapyCytotoxic T cellCD8CTL*Tumor microenvironmentT cellImmunologyCancer immunotherapyCancer researchAntibodyMedicineImmune systemMelanomaBiologyIn vitroBiochemistryImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkersvaccines and immunoinformatics approaches
Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model | Litcius